Zentalis Historical Balance Sheet

ZNTL Stock

USD 2.15 0.03 1.42%

Trend analysis of Zentalis Pharmaceuticals Llc balance sheet accounts such as Total Assets of 376.7 M, Other Current Liab of 65.4 M, Total Current Liabilities of 40.3 M or Total Stockholder Equity of 306.3 M provides information on Zentalis Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Zentalis Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Zentalis Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Zentalis Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Zentalis Pharmaceuticals is a good buy for the upcoming year.

Zentalis Pharmaceuticals Inventory

(6.65 Million)

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About Zentalis Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Zentalis Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Zentalis Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Zentalis Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Zentalis currently owns. An asset can also be divided into two categories, current and non-current.

Zentalis Pharmaceuticals Balance Sheet Chart

At this time, Zentalis Pharmaceuticals' Other Assets are quite stable compared to the past year. Net Receivables is expected to rise to about 8.5 M this year, although the value of Total Current Liabilities will most likely fall to about 40.3 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity Common Stock Total Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Zentalis Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Zentalis Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Zentalis Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Zentalis Pharmaceuticals Llc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most accounts from Zentalis Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Zentalis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	45.4M	54.2M	62.3M	65.4M
Total Assets	539.3M	551.7M	634.4M	376.7M

Other Current Liab Total Assets

Zentalis Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.92	0.98	1.0	0.25	0.96	0.93	0.6	-0.92	0.98	0.27	0.85	0.57	0.93	1.0	0.84	-0.4	-0.87	0.96	0.93	0.89	0.92	0.97	1.0	0.8	1.0
Other Current Liab	0.92		0.93	0.91	0.25	0.96	0.86	0.72	-0.98	0.92	0.16	0.77	0.77	0.98	0.92	0.96	-0.69	-0.81	0.93	0.88	0.82	1.0	0.92	0.91	0.87	0.92
Total Current Liabilities	0.98	0.93		0.97	0.33	0.92	0.92	0.65	-0.95	0.99	0.18	0.81	0.65	0.92	0.98	0.88	-0.42	-0.83	0.98	0.95	0.85	0.93	0.99	0.97	0.81	0.98
Total Stockholder Equity	1.0	0.91	0.97		0.23	0.96	0.91	0.57	-0.91	0.98	0.29	0.84	0.56	0.91	1.0	0.82	-0.4	-0.88	0.96	0.91	0.89	0.92	0.96	1.0	0.78	1.0
Other Liab	0.25	0.25	0.33	0.23		0.09	0.15	-0.16	-0.29	0.24	0.34	0.02	0.1	0.12	0.27	0.25	0.08	-0.4	0.43	0.2	0.35	0.23	0.28	0.27	-0.06	0.27
Net Tangible Assets	0.96	0.96	0.92	0.96	0.09		0.88	0.69	-0.94	0.94	0.2	0.83	0.65	0.97	0.96	0.89	-0.59	-0.83	0.9	0.89	0.86	0.97	0.92	0.95	0.84	0.96
Property Plant And Equipment Net	0.93	0.86	0.92	0.91	0.15	0.88		0.67	-0.86	0.92	0.23	0.97	0.47	0.91	0.9	0.83	-0.35	-0.77	0.86	0.99	0.83	0.85	0.97	0.91	0.83	0.9
Net Debt	0.6	0.72	0.65	0.57	-0.16	0.69	0.67		-0.76	0.64	-0.5	0.57	0.6	0.8	0.58	0.84	-0.55	-0.23	0.54	0.71	0.55	0.71	0.68	0.54	0.68	0.59
Retained Earnings	-0.92	-0.98	-0.95	-0.91	-0.29	-0.94	-0.86	-0.76		-0.94	-0.09	-0.75	-0.77	-0.97	-0.92	-0.96	0.6	0.78	-0.93	-0.89	-0.81	-0.98	-0.94	-0.9	-0.85	-0.92
Accounts Payable	0.98	0.92	0.99	0.98	0.24	0.94	0.92	0.64	-0.94		0.19	0.81	0.67	0.92	0.98	0.85	-0.43	-0.83	0.97	0.93	0.81	0.93	0.98	0.97	0.85	0.98
Cash	0.27	0.16	0.18	0.29	0.34	0.2	0.23	-0.5	-0.09	0.19		0.33	-0.06	0.09	0.26	-0.04	0.01	-0.68	0.29	0.17	0.22	0.17	0.18	0.34	0.17	0.26
Non Current Assets Total	0.85	0.77	0.81	0.84	0.02	0.83	0.97	0.57	-0.75	0.81	0.33		0.32	0.84	0.81	0.72	-0.3	-0.74	0.74	0.94	0.78	0.76	0.88	0.85	0.77	0.81
Non Currrent Assets Other	0.57	0.77	0.65	0.56	0.1	0.65	0.47	0.6	-0.77	0.67	-0.06	0.32		0.69	0.6	0.72	-0.78	-0.51	0.68	0.51	0.29	0.78	0.6	0.56	0.82	0.6
Other Assets	0.93	0.98	0.92	0.91	0.12	0.97	0.91	0.8	-0.97	0.92	0.09	0.84	0.69		0.91	0.96	-0.65	-0.76	0.89	0.92	0.84	0.98	0.94	0.91	0.87	0.92
Cash And Short Term Investments	1.0	0.92	0.98	1.0	0.27	0.96	0.9	0.58	-0.92	0.98	0.26	0.81	0.6	0.91		0.83	-0.41	-0.87	0.97	0.91	0.88	0.92	0.96	0.99	0.78	1.0
Net Receivables	0.84	0.96	0.88	0.82	0.25	0.89	0.83	0.84	-0.96	0.85	-0.04	0.72	0.72	0.96	0.83		-0.69	-0.65	0.84	0.86	0.8	0.95	0.88	0.81	0.79	0.83
Good Will	-0.4	-0.69	-0.42	-0.4	0.08	-0.59	-0.35	-0.55	0.6	-0.43	0.01	-0.3	-0.78	-0.65	-0.41	-0.69		0.4	-0.45	-0.36	-0.31	-0.69	-0.4	-0.4	-0.65	-0.41
Common Stock Total Equity	-0.87	-0.81	-0.83	-0.88	-0.4	-0.83	-0.77	-0.23	0.78	-0.83	-0.68	-0.74	-0.51	-0.76	-0.87	-0.65	0.4		-0.88	-0.75	-0.76	-0.82	-0.8	-0.91	-0.71	-0.87
Common Stock Shares Outstanding	0.96	0.93	0.98	0.96	0.43	0.9	0.86	0.54	-0.93	0.97	0.29	0.74	0.68	0.89	0.97	0.84	-0.45	-0.88		0.89	0.82	0.93	0.95	0.96	0.79	0.97
Non Current Liabilities Total	0.93	0.88	0.95	0.91	0.2	0.89	0.99	0.71	-0.89	0.93	0.17	0.94	0.51	0.92	0.91	0.86	-0.36	-0.75	0.89		0.83	0.87	0.98	0.92	0.83	0.91
Other Current Assets	0.89	0.82	0.85	0.89	0.35	0.86	0.83	0.55	-0.81	0.81	0.22	0.78	0.29	0.84	0.88	0.8	-0.31	-0.76	0.82	0.83		0.81	0.85	0.89	0.52	0.88
Other Stockholder Equity	0.92	1.0	0.93	0.92	0.23	0.97	0.85	0.71	-0.98	0.93	0.17	0.76	0.78	0.98	0.92	0.95	-0.69	-0.82	0.93	0.87	0.81		0.92	0.92	0.88	0.93
Total Liab	0.97	0.92	0.99	0.96	0.28	0.92	0.97	0.68	-0.94	0.98	0.18	0.88	0.6	0.94	0.96	0.88	-0.4	-0.8	0.95	0.98	0.85	0.92		0.96	0.83	0.96
Net Invested Capital	1.0	0.91	0.97	1.0	0.27	0.95	0.91	0.54	-0.9	0.97	0.34	0.85	0.56	0.91	0.99	0.81	-0.4	-0.91	0.96	0.92	0.89	0.92	0.96		0.79	0.99
Property Plant And Equipment Gross	0.8	0.87	0.81	0.78	-0.06	0.84	0.83	0.68	-0.85	0.85	0.17	0.77	0.82	0.87	0.78	0.79	-0.65	-0.71	0.79	0.83	0.52	0.88	0.83	0.79		0.78
Total Current Assets	1.0	0.92	0.98	1.0	0.27	0.96	0.9	0.59	-0.92	0.98	0.26	0.81	0.6	0.92	1.0	0.83	-0.41	-0.87	0.97	0.91	0.88	0.93	0.96	0.99	0.78

Click cells to compare fundamentals

Zentalis Pharmaceuticals Account Relationship Matchups

Zentalis Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	365.6M	454.5M	539.3M	551.7M	634.4M	376.7M
Other Current Liab	18.6M	29.9M	45.4M	54.2M	62.3M	65.4M
Total Current Liabilities	28.6M	43.9M	56.6M	69.4M	79.8M	40.3M
Total Stockholder Equity	333.4M	364.5M	434.0M	437.3M	502.9M	306.3M
Other Liab	4.2M	2.5M	1.6M	3.5M	3.1M	2.3M
Net Tangible Assets	(92.6M)	296.0M	360.2M	433.8M	498.9M	523.8M
Property Plant And Equipment Net	3.6M	52.8M	50.1M	41.7M	48.0M	27.8M
Net Debt	(53.0M)	(13.8M)	2.1M	15.1M	17.4M	18.2M
Retained Earnings	(200.8M)	(359.6M)	(596.4M)	(888.6M)	(799.7M)	(759.7M)
Accounts Payable	8.7M	11.6M	11.2M	14.9M	17.2M	9.9M
Cash	55.0M	59.7M	43.1M	28.0M	25.2M	39.1M
Non Current Assets Total	20.5M	103.7M	87.4M	55.0M	63.2M	54.9M
Non Currrent Assets Other	2.3M	2.6M	(1.8M)	9.5M	10.9M	11.5M
Other Assets	0.0	4.3M	9.7M	12.4M	14.2M	14.9M
Cash And Short Term Investments	338.5M	339.9M	437.4M	482.9M	555.4M	312.8M
Net Receivables	140K	417K	2.6M	7.0M	8.1M	8.5M
Common Stock Total Equity	25K	41K	45K	59K	53.1K	50.4K
Common Stock Shares Outstanding	41.0M	42.7M	52.9M	65.4M	75.2M	46.9M
Liabilities And Stockholders Equity	365.6M	454.5M	539.3M	551.7M	634.4M	376.7M
Non Current Liabilities Total	3.6M	46.1M	48.6M	44.9M	51.7M	27.5M
Capital Lease Obligations	2.0M	45.9M	45.2M	43.2M	49.6M	25.1M
Other Current Assets	11.2M	8.0M	29.1M	13.8M	15.9M	11.8M
Other Stockholder Equity	509.3M	723.6M	1.0B	1.3B	1.5B	1.6B
Total Liab	32.2M	90.0M	105.3M	114.3M	131.4M	67.7M
Net Invested Capital	308.6M	364.0M	433.8M	437.3M	502.9M	290.6M
Property Plant And Equipment Gross	3.6M	53.6M	7.7M	44.9M	51.6M	54.2M
Total Current Assets	345.1M	350.8M	451.9M	496.7M	571.2M	321.8M
Accumulated Other Comprehensive Income	36K	(125K)	(1.4M)	2.2M	2.5M	2.6M
Capital Stock	41K	45K	59K	70K	63K	59.9K
Net Working Capital	316.5M	306.8M	395.3M	427.4M	491.5M	281.5M
Common Stock	41K	45K	59K	70K	63K	59.9K
Property Plant Equipment	2.8M	3.6M	8.1M	7.7M	8.9M	5.0M
Short Long Term Debt Total	2.0M	45.9M	45.2M	43.2M	49.6M	30.1M
Short Term Debt	902K	1.5M	2.2M	2.6M	3.0M	1.7M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:

How To Invest In Zentalis

Details

Is Zentalis Stock a good investment?

Details

What is Zentalis Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.50)

Revenue Per Share

0.572

Return On Assets

(0.25)

Return On Equity

(0.43)

The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zentalis Historical Balance Sheet

Zentalis Pharmaceuticals Inventory

(6.65 Million)

About Zentalis Balance Sheet Analysis

Zentalis Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Common Stock Total Equity

Zentalis Pharmaceuticals balance sheet Correlations

Zentalis Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zentalis Pharmaceuticals balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Other Stockholder Equity	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity

Other Stockholder Equity	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Other Current Liab
Other Assets	- 0.97	Retained Earnings
Net Receivables	- 0.96	Retained Earnings
Retained Earnings	- 0.95	Total Current Liabilities
Total Liab	- 0.94	Retained Earnings